Literature DB >> 3612292

Investigations of avidin and biotin for imaging applications.

D J Hnatowich, F Virzi, M Rusckowski.   

Abstract

The attractive properties of avidin (streptavidin) and biotin, in particular their strong affinities (Kd = 10(-15)M), may be used to advantage in imaging applications. These molecules have been used in this preliminary investigation to improve the targeting of 111In in animals. Antibodies have been conjugated with biotin and administered unlabeled while, at a later time, the radiolabel was administered attached to DTPA-coupled avidin or streptavidin. An alternative procedure was also considered whereby the antibodies were conjugated with avidin and administered before the administration of radiolabeled biotin. Using a model in which the target consisted of conjugated agarose beads deposited in the peritoneum of mice, it has been shown that the target/nontarget radioactivity ratios may be significantly improved with respect to the conventional procedures through the use of this approach.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612292

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  88 in total

1.  Accelerated Blood Clearance of Antibodies by Nanosized Click Antidotes.

Authors:  Weston J Smith; Guankui Wang; Hanmant Gaikwad; Vivian P Vu; Ernest Groman; David W A Bourne; Dmitri Simberg
Journal:  ACS Nano       Date:  2018-12-05       Impact factor: 15.881

2.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-Francois Chatal; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-06       Impact factor: 9.236

3.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

4.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Authors:  Steven I Park; Jaideep Shenoi; Shani M Frayo; Donald K Hamlin; Yukang Lin; D Scott Wilbur; Patrick S Stayton; Nural Orgun; Mark Hylarides; Franz Buchegger; Aimee L Kenoyer; Amanda Axtman; Ajay K Gopal; Damian J Green; John M Pagel; Oliver W Press
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

Review 5.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  A novel pretargeting method for measuring antibody internalization in tumor cells.

Authors:  Guozheng Liu; Shuping Dou; Dongguang Yin; Shayne Squires; Xinrong Liu; Yi Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biother Radiopharm       Date:  2007-02       Impact factor: 3.099

7.  Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry.

Authors:  Holly A Bilton; Zainab Ahmad; Nancy Janzen; Shannon Czorny; John F Valliant
Journal:  J Vis Exp       Date:  2017-02-04       Impact factor: 1.355

8.  Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.

Authors:  Gui-Ping Li; Hui Zhang; Cheng-Mo Zhu; Jian Zhang; Xu-Feng Jiang
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

9.  Differential underacetylation of histones H2A, H3 and H4 on the inactive X chromosome in human female cells.

Authors:  N Belyaev; A M Keohane; B M Turner
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

10.  Immunotargeting of antioxidant enzyme to the pulmonary endothelium.

Authors:  V R Muzykantov; E N Atochina; H Ischiropoulos; S M Danilov; A B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.